Nucleic Acid, Nucleoside, or Nucleotide – Page 2

Post-Hoc: AI bio needs to heed the overhyped history of CRISPR

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, overhype, reproductive health biotech

CRISPR; AI in biotech; overhype; gene editing; reproductive health biotech

CRISPR Therapeutics Partners with Sirius for siRNA Therapies, Expanding Beyond Gene Editing

2 months ago talkbio0Tagged Anticoagulants, biotech partnerships, Cardiovascular Diseases, Clustered Regularly Interspaced Short Palindromic Repeats, Factor XI, Gene Modification, RNA, Small Interfering, Sirius, SRSD107, thrombotic disease

CRISPR Therapeutics; Sirius Therapeutics; siRNA; gene editing; SRSD107; cardiovascular diseases; thrombotic disease; biotech partnerships; Factor XI; anticoagulant therapies

AbbVie Commits $335M Upfront in Landmark siRNA Deal With ADARx

2 months ago talkbio0Tagged AbbVie, ADARx, biotech partnerships, Drug Development, Gene Silencing, Immunology, Neoplasms, Neuroscience discipline, RNA technology, RNA, Small Interfering

AbbVie; ADARx Pharmaceuticals; siRNA therapeutics; gene silencing; neuroscience; immunology; oncology; biotech partnerships; RNA technology; drug development

Federal Appeals Court Revives CRISPR Patent Dispute Between Broad Institute and University of California

2 months ago talkbio0Tagged Broad Institute, Clustered Regularly Interspaced Short Palindromic Repeats, Eukaryotic Cells, Federal Circuit, Gene Modification, Intellectual Property, Legal patent, PTAB, University of California

CRISPR; patent dispute; Broad Institute; University of California; Federal Circuit; PTAB; gene editing; intellectual property; eukaryotic cells

Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Dark color, Eli, Eli Lilly, Genome, Haya, Long Intergenic Non-Protein Coding RNA, Obesity

Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color

CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

3 months ago talkbio0Tagged cholesterol, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, CTX310, Gene Modification, Genes, In Vivo, LDL Cholesterol Lipoproteins, Triglycerides

Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes

Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

3 months ago talkbio0Tagged Dependovirus, gene therapy, Industry, Partnership, research, Safety, Transfer RNA

gene therapy, Dependovirus, Transfer RNA, Partnership, Industry, research, Safety

Novartis to buy Regulus Therapeutics for up to $1.7B

3 months ago talkbio0Tagged Acquisition (action), Goldcrest, Kidney Diseases, Novartis

Goldcrest, Novartis, Acquisition (action), Kidney Diseases

Lilly taps Creyon’s AI-enabled oligo tech in heavily backloaded $1B deal

3 months ago talkbio0Tagged Creyon, Eli, Eli Lilly, Oligonucleotides

Creyon, Eli Lilly, Eli, Oligonucleotides

As J&J aims to ‘fundamentally change’ how bladder cancer type is treated, ImmunityBio plays defense

3 months ago talkbio0Tagged Anktiva, BCG-Unresponsive, bladder-sparing treatment, Carcinoma in Situ, gemcitabine releasing system, ImmunityBio, in situ, Malignant neoplasm of urinary bladder, Non-Muscle Invasive Bladder Neoplasms, TAR 200

TAR-200, bladder cancer, gemcitabine releasing system, non-muscle invasive bladder cancer (NMIBC), Johnson & Johnson, ImmunityBio, Anktiva, BCG-unresponsive, carcinoma in situ (CIS), bladder-sparing treatment